Cell reports:YAP抑制晚期肝癌细胞分化治疗肝癌新策略

2015-03-19 佚名 生物谷

                                                        &nb

                                                                

近日,来自美国的科学家在国际期刊cell reports发表了他们的最新研究进展,他们发现在肝脏中激活Hippo途径中的YAP活性能够抑制肝脏细胞分化,并且这种效应在晚期肝癌中也存在,同时在晚期肝癌细胞中抑制YAP活性能够重建肝脏分化过程,导致肿瘤回归。
 
肝细胞癌(HCC)是一种常见癌症类型,在美国人群中的发生率逐年增加。研究人员根据基因组研究结果将HCC划分为不同亚型,具有不同的分子和临床特征。Hippo信号途径是一种重要的肿瘤抑制途径,在包括肝脏在内的多种组织器官中具有重要作用。肝脏中Hippo/YAP信号途径缺陷会导致肝脏过度生长并发展为肝细胞癌。
 
为研究YAP在HCC发展和维持过程中的作用,确定其下游癌基因表达谱,研究人员利用基因操作方法和siRNA-LNP技术对基因工程小鼠进行了一系列研究。结果发现,激活内源性YAP能够扰乱肝脏细胞分化过程,并在晚期肿瘤中维持这种状态。在HCC中抑制YAP活性能够重建肝脏细胞分化过程,并导致肿瘤的回归。
 
这些结果表明抑制细胞分化过程是治疗内皮肿瘤的一种潜在治疗策略,而且siYAP-LNP诱导的显著应答反应也支持了这种治疗方式的临床发展。
 
原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]
    2015-05-24 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]
    2015-04-14 gujh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]
    2015-03-21 yxch36
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1869046, encodeId=b5561869046d5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 02 12:09:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959297, encodeId=57ab195929e22, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 24 05:09:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081881, encodeId=f1d62081881eb, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Tue Apr 14 00:09:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976355, encodeId=756919e635500, content=<a href='/topic/show?id=0ae08128e66' target=_blank style='color:#2F92EE;'>#肝癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81287, encryptionId=0ae08128e66, topicName=肝癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Sun May 03 22:09:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252022, encodeId=71251252022b6, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478356, encodeId=725314e8356f3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570161, encodeId=439615e016105, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Sat Mar 21 00:09:00 CST 2015, time=2015-03-21, status=1, ipAttribution=)]

相关资讯

新生儿接种乙肝疫苗可降低未来肝癌发病风险

一项最新研究结果显示,新生儿乙肝疫苗接种可降低青壮年肝癌及乙肝病毒(HBV)感染相关肝脏疾病的发病风险。这项研究由中国医学科学院肿瘤医院分子肿瘤学国家重点实验室的曲春枫,启东肝癌防治研究所的陈陶阳以及耶鲁大学医学院公共卫生学院的张亚玮等人共同开展,结果发表在近期的《公共科学图书馆·医学》(PLOS Medicine)上。记者对主要研究者曲春枫教授进行了采访。 慢性乙肝病毒感染是肝癌发生的重要

非酒精性脂肪肝生物标志物已经被识别

在欧盟国家中有40%的个体都遭受着非酒精性脂肪性肝炎的痛苦,在当前富裕社会下这种疾病的流行率越来越高,其也是个体糖尿病和体重过度增加的直接结果,当前研究者并不可能预测这种疾病的未来发展情况,而其直接的结果似乎只能是肝硬化和肝癌,此外其也会增加个体患心脏病发作及肾脏损伤的风险,未来研究者或将利用不同生物标志物的风险评分来对该疾病进行预测。 来自维也纳医科大学的研究者表示,我们开发的这种风险

JCI:氧化应激或促进肝癌发生

近日,著名临床医学类杂志the journal of clinical investigation在线发表了法国科学家的一项最新研究进展,他们发现氧化应激会促进非酒精脂肪肝(NAFLD)发生病理性多倍体化,而这种病理性变化会进一步促进肝癌发生。这一研究成果或许对预防非酒精性脂肪肝诱导的肝癌具有重要意义。   多倍体化是基因组可能发生的一个非常巨大的变化,在肝脏中,生理性多倍体化在肝脏

ASCO GI 2015 :REACH研究亚组分析:基线AFP水平或成为RAM治疗晚期肝癌OS获益的标志物

REACH研究亚组分析:ramucirumab二线治疗晚期肝细胞癌患者生存获益与基线高AFP水平的关系(摘要号:232) 报告者:Andrew X. Zhu 报告时间:旧金山时间1月16日,10:30 am~12:00 pm 研究背景 REACH研究是一项全球、多中心、随机、双盲、Ⅲ期研究,评价ramucirumab(RAM)单药治疗对索拉非尼一线治疗后晚期肝细胞癌患者的疗效和安全性。RE

PLoS Med:新生儿乙肝疫苗接种可降低肝癌的发病

一项最新研究结果显示,新生儿乙肝疫苗接种可降低青壮年肝癌及乙肝病毒(HBV)感染相关肝脏疾病的发病风险。这项研究由中国医学科学院肿瘤医院分子肿瘤学国家重点实验室的曲春枫,启东肝癌防治研究所的陈陶阳以及耶鲁大学医学院公共卫生学院的张亚玮等人共同开展,结果发表在近期的《公共科学图书馆·医学》(PLOS Medicine)上。果壳网科学人对主要研究者曲春枫教授进行了采访。 慢性乙肝病毒感染是肝

Nat Commun:全基因组测序揭示肝炎与肝癌新联系

最近,日本理化学所(RIKEN)的科学家们,利用全基因组测序首次证实,慢性肝炎和炎症可能对肝脏肿瘤中发现的基因突变产生深远的影响,从而为更好理解慢性肝炎导致癌症的机制,铺平了道路。相关研究结果发表在最近的《自然通讯》(Nature Communications)。 原发性肝癌是全世界癌症死亡的第三大原因,最近的研究表明,特别是在亚洲,感染乙型或丙型肝炎病毒,往往与这类癌症有关。肝癌从细